CN100345554C - Compounding medicinal capsule for treating angiitis - Google Patents

Compounding medicinal capsule for treating angiitis Download PDF

Info

Publication number
CN100345554C
CN100345554C CNB200510040918XA CN200510040918A CN100345554C CN 100345554 C CN100345554 C CN 100345554C CN B200510040918X A CNB200510040918X A CN B200510040918XA CN 200510040918 A CN200510040918 A CN 200510040918A CN 100345554 C CN100345554 C CN 100345554C
Authority
CN
China
Prior art keywords
radix
medicine
powder
fine powder
angelicae sinensis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB200510040918XA
Other languages
Chinese (zh)
Other versions
CN1723972A (en
Inventor
李伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB200510040918XA priority Critical patent/CN100345554C/en
Publication of CN1723972A publication Critical patent/CN1723972A/en
Application granted granted Critical
Publication of CN100345554C publication Critical patent/CN100345554C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention discloses a Chinese and western medicine compound capsule for treating angitis. 3 to 10 portions of ginseng, 10 to 40 portions of achyranthes roots, 20 to 40 portions of angelica and 10 to 40 of hemlock parsley are used as raw materials. After affective ingredients are decocted with water and extracted, the affective ingredients are mixed with daily dose of 190 to 570 mg of aspirin, 30 to 110 mg of oryzanol, 40 to 150 mg of rutin, 120 to 400 mg of VC, 20 to 50 mg of dibazole, 220 to 700 mg of glucurolactone, 6 to 19 mg of anisodamine; then, the mixture is pulverized into fine powder to be encapsulated, and the finished product medicine is made. Through clinical verification, the present invention has the advantages of treating both manifestation and root causes of disease, not relapsing after cure, etc. The effective rate is as high as 100%; toxic and side effects do not exist. The medicine of the present invention is suitable for treating angitis and deep vein barrage, and also has quite therapeutic effect on cerebral blood vessel rigidification.

Description

The vasculitic compound capsule of a kind of treatment
Technical field
The present invention relates to a kind of medicine, specifically be meant a kind of medicine for the treatment of thromboangiitis obliterans.
Background technology
Thromboangiitis obliterans claims thromboangiitis obliterans again, is called for short vasculitis, is one of dangerous disease of surgery of Chinese medicine.Its cause of disease is still not exclusively to understand so far.Mostly the patient is that person between twenty and fifty, the overwhelming majority are the male.
The method of treatment thromboangiitis obliterans is roughly as follows at present:
1, doctor trained in Western medicine: Drug therapy: for the patient of first and second phase based on vasodilator, as parathyrine E (PGE) and α receptor blocking agent, beta receptor analeptic: scoline, benzazoline etc. in the change.Be aided with broad ectrum antibiotic and analgesic again.Can obtain certain curative effect.And only can give potent analgesic for the patient of the third phase, do not play the medicine of therapeutical effect.Operative treatment: (1), sympathectomy: only the part patient for first and second phase can obtain short-term effect.(2), artery reconstruction art: the small number of patients that is only applicable to tremulous pulse trunk office section obturation.(3), free vessel pedicle omentum grafting: operating difficulty is big, and the patient suffering is big, and trouble limb functional rehabilitation is not good enough.(4), arteriovenous shunt by stages: patient suffering's great achievement power is low, and some underlying issue remains further investigation.(5), amputation: the patient for the third phase only can adopt this kind operation at present, stays deformity to the patient.
2, the traditional Chinese medical science: 1, cloudy plug type: add and subtract with YANGHE TANG; (2), damp-heat type: add flavor or Herba Artemisiae Scopariae Semen Phaseoli vapour plus-minus with SIMIAOYONGAN TANG; (3) heat-toxin type: with the SIMIAOYONGAN TANG plus-minus, to get its heat-clearing and toxic substances removing, the merit of blood circulation promoting and blood stasis dispelling is difficult to cure but clinical treatment is but only got better; (4) both Qi and blood deficiency: Tonga subtracts with the Gu step.Above-mentioned decoction is played a role to this condition of disease, but effect is unsatisfactory, be difficult to effect a radical cure fully, and easily recurrence.
Summary of the invention
The purpose of this invention is to provide a kind of medicament capsule with the bonded treatment thromboangiitis obliterans of Chinese medicine and western medicine, it can fundamentally solve patient's misery, make the systolic and diastolic function of small artery autonomy recover normal by the vegetative nerve of regulating limb vessel, the ischemic region blood circulation is improved, reach the purpose of radical cure thromboangiitis obliterans.
The present invention realizes with following technical scheme: the vasculitic compound capsule of a kind of treatment, it is characterized in that Radix Ginseng is worn into fine powder, with Radix Cyathulae, Radix Angelicae Sinensis, Rhizoma Chuanxiong four flavor raw material of Chinese medicine after decocting extracts and Western medicine make, wherein the weight portion of each crude drug of Chinese medicine is:
Radix Ginseng 3-10 part Radix Cyathulae 10-40 part
Radix Angelicae Sinensis 20-40 part Rhizoma Chuanxiong 10-40 part
Dosage every day of every kind of medicine of Western medicine is:
Aspirin 190-630mg oryzanol 30-110mg
Rutin 40-150mg VC 120-400mg
Bendazol 20-50mg Glucuronic acid lactone 220-700mg
Anisodamine 6-19mg
Each crude drug of the present invention and consumption thereof be the inventor carry out a large amount of clinical grope to sum up draw, each raw material consumption all has better curative effect in above-mentioned scope.
The preparation method of medicine of the present invention is as follows:
1) take by weighing various material medicines in proportion, standby;
2) Radix Ginseng powder is broken into fine powder, standby;
3) Radix Cyathulae, Radix Angelicae Sinensis, Rhizoma Chuanxiong three flavor Chinese medicines are decocted with water secondary, decocted 1-1.5 hour at every turn, slagging-off gets filtrate;
4) merge secondary filtrate, be concentrated into the clear paste of relative density about 1.30 (50 ℃ of surveys);
5) the Radix Ginseng fine powder is added mixing in the clear paste, and add appropriate amount of starch;
6) powder during crushed after being dried becomes;
7) middle powder adding aspirin, oryzanol, rutin, VC, bendazol, Glucuronic acid lactone, Anisodamine mixed grinding are crossed 100 mesh sieves;
8) medicated powder is packed into Capsules gets finished product.
Medicine of the present invention wherein Chinese medicine Radix Ginseng, Radix Angelicae Sinensis have enrich blood, inrigorating qi and promoting blood circulation promotes the production of body fluid Rhizoma Chuanxiong, Radix Cyathulae: have promoting blood circulation and stopping pain, the dampness removing that stimulates the menstrual flow is regulated descending effect.Effect with inrigorating qi and promoting blood circulation; that aspirin in the Western medicine has is analgesic, analgesia, antiinflammatory, anticoagulant effect; it is synthetic that prolonged application also can suppress the liver thrombinogen, and Glucuronic acid lactone is an important detoxifcation material in the body, and the liver protecting and Detoxication are arranged.Oryzanol, rutin, VC, Anisodamine and bendazol, have the vegetative nerve of regulating limb vessel and make the systolic and diastolic function of small artery autonomy recover normal, keep blood vessel elasticity, reduce its fragility, improve the ischemic region blood circulation, thereby reach " mark ", " basis " double purpose of controlling.
The specific embodiment
Below in conjunction with embodiment and further auspicious using method of the present invention and the effect stated of experimental example.
Embodiment 1
The raw material prescription:
Radix Ginseng 30g Radix Cyathulae 400g
Radix Angelicae Sinensis 500g Rhizoma Chuanxiong 400g
Aspirin 63g oryzanol 11g
Rutin 13.8g VC 35g
Bendazol 5.5g Glucuronic acid lactone 70g
Anisodamine 2.1mg
Preparation method:
The Radix Ginseng powder is broken into fine powder; Radix Cyathulae, Radix Angelicae Sinensis, Rhizoma Chuanxiong are merged the water decocting method to be extracted 2 times, the each decoction 1-1.5 hour, after the slagging-off with twice filtrate complete and after be concentrated into the clear paste of relative density about 1.30, the Radix Ginseng fine powder is added in the clear paste mixing and adds appropriate amount of starch, mix equal after drying; The grain weight amount was 399.6g during crushed after being dried became; Aspirin, oryzanol, rutin, VC, bendazol, Glucuronic acid lactone, Anisodamine and Chinese medicine powder mixed grinding are crossed 100 mesh sieves, in the Capsules of packing into.By every capsules medicated powder 0.60g that packs into, can prepare 1000 of capsules.
Test example: the vasculitic clinical observation of Drug therapy of the present invention.
1, physical data:
To control clinical patients 150 examples, wherein two lower limb vasculitiss account for 85%, and the upper limb vasculitis accounts for 15%, and the course of disease is the shortest 6 months, and the longest 27 years, simple ulcer accounts for 30%, and the lower limb gangrene accounts for 15%; Age of onset 20-40 year.
2, diagnostic criteria:
As follows according to the diagnostic criteria that CAIM (Chinese Association Of Integrative Medicine) peripheral vascular disease Professional Committee works out nineteen ninety-five:
1) mostly is the male, age of onset 20-40 year.
2) performance of chronic limb artery ischemic is arranged: send out cool, be afraid of cold, numbness, intermittent limping, congestion, malnutrition change etc., often involve lower limb, it is few that upper limb is sent out the patient.
3) 40%-60% has migration row superficial thrombophlebitis medical history and sign.
4) various Inspection Certificates, limb artery is narrow, inaccessible position Duo Zai popliteal tremulous pulse and distal artery thereof (often involve in the limbs, small artery).
5) smoking history is almost arranged entirely, or catch cold and freeze history.
6) in the disease activity phase, IgG, IgA, the anti-tremulous pulse antibody of IgM in the blood samples of patients, the immune complex positive rate increases, and the T cell function reduces.
7) angiography: pathological changes is many, and tremulous pulse is segmental obturation, narrow at thigh, popliteal tremulous pulse and distal artery thereof, and the many genus of tremulous pulse between the inaccessible section and proximal part tremulous pulse are normal, and arterial occlusive nearly far-end has tree root shape side Zhi Xunhuan tremulous pulse more.
3, Therapeutic Method:
Oral capsule 0.6g/ grain of the present invention, every day 3 times, each 2-3 grain, 1 month is a course of treatment.General treatment 6-8 course of treatment.
4, criterion of therapeutical effect:
Cure: cardinal symptom disappears, wound healing.
Produce effects: sx, wound dwindle, blood samples of patients circulatory disturbance has improvement, still need treat.
Invalid: the treatment more than two months sings and symptoms do not have obvious change.
5, therapeutic effect
Cure 146 routine cure rates 97.3%
Produce effects 4 routine obvious effective rates 2.7%
Invalid 0 routine inefficiency 0%

Claims (2)

1, the vasculitic compound capsule of a kind of treatment is characterized in that Radix Ginseng wears into fine powder, with Radix Cyathulae, Radix Angelicae Sinensis, Rhizoma Chuanxiong three flavor raw material of Chinese medicine after decocting extracts and Western medicine make, wherein the weight portion of each crude drug of Chinese medicine is:
Radix Ginseng 3-10 part Radix Cyathulae 10-40 part
Radix Angelicae Sinensis 20-40 part Rhizoma Chuanxiong 10-40 part
Dosage every day of every kind of medicine of Western medicine is:
Aspirin 190-630mg oryzanol 30-110mg
Rutin 40-150mg VC 120-400mg
Bendazol 20-50mg Glucuronic acid lactone 220-700mg
Anisodamine 6-19mg.
2, the described a kind of preparation method for the treatment of vasculitic compound capsule of claim 1 is characterized in that carrying out as follows:
1) take by weighing various material medicines in proportion, standby;
2) Radix Ginseng powder is broken into fine powder, standby;
3) Radix Cyathulae, Radix Angelicae Sinensis, Rhizoma Chuanxiong three flavor Chinese medicines are decocted with water secondary, decocted 1-1.5 hour at every turn, slagging-off gets filtrate;
4) merge secondary filtrate, measure the clear paste that is concentrated into relative density about 1.30 down at 50 ℃;
5) the Radix Ginseng fine powder is added mixing in the clear paste, and add appropriate amount of starch;
6) powder during crushed after being dried becomes;
7) middle powder adding aspirin, oryzanol, rutin, VC, bendazol, Glucuronic acid lactone, Anisodamine mixed grinding are crossed 100 mesh sieves;
8) Capsules of packing into gets finished product.
CNB200510040918XA 2005-07-04 2005-07-04 Compounding medicinal capsule for treating angiitis Expired - Fee Related CN100345554C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB200510040918XA CN100345554C (en) 2005-07-04 2005-07-04 Compounding medicinal capsule for treating angiitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB200510040918XA CN100345554C (en) 2005-07-04 2005-07-04 Compounding medicinal capsule for treating angiitis

Publications (2)

Publication Number Publication Date
CN1723972A CN1723972A (en) 2006-01-25
CN100345554C true CN100345554C (en) 2007-10-31

Family

ID=35923689

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200510040918XA Expired - Fee Related CN100345554C (en) 2005-07-04 2005-07-04 Compounding medicinal capsule for treating angiitis

Country Status (1)

Country Link
CN (1) CN100345554C (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108619364A (en) * 2018-08-01 2018-10-09 李伟 A kind of drug and preparation method thereof for treating diabetes vasculitis disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1224614A (en) * 1998-01-24 1999-08-04 倪德贵 Medicine for preventing and curing cardiac and cerebral vascular diseases and its preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1224614A (en) * 1998-01-24 1999-08-04 倪德贵 Medicine for preventing and curing cardiac and cerebral vascular diseases and its preparation

Also Published As

Publication number Publication date
CN1723972A (en) 2006-01-25

Similar Documents

Publication Publication Date Title
CN1476849A (en) Medicine composition for promoting blood circulation and removing stasis
CN1091609C (en) Tincture for treating rheumatoid arthritis and its preparing process
CN1232266C (en) Chinese medicinal capsules for apoplexy and thoracic palsy and preparation thereof
CN1117582C (en) medicine for treating rheumatoid arthritis and preparing process thereof
CN100345554C (en) Compounding medicinal capsule for treating angiitis
CN101032604A (en) Chinese medicine preparation for curing vascular type headache
CN1159030C (en) Capsule 'Jingmaitong'
CN1843421A (en) Rheumatoid disease treating medicine
CN102198181B (en) Antithrombotic and thrombosis-eliminating preparation
CN1186065C (en) Externally applied medicinal stasis-and swelling-eliminating powder for treating chronic pelvic inflammation
CN1947791A (en) External use traditional Chinese medicine ointment for treating heart diseases
CN1879783A (en) A medicine for treating diabetes
CN103585414B (en) Pharmaceutical composition for treating sciatica and osteoporosis
CN1241603C (en) Bone joint disease capsule and its manufacturing metod
CN106214828A (en) A kind of Chinese medicine of passage, nourishing blood and preparation method thereof
CN1176690C (en) Medicine for treating chronic nephritis
CN1709400A (en) Medicine for treating ulcer haemorrhage
CN1246027C (en) Medicine for treating high blood pressure and its preparation method
CN1279951C (en) Pure Chinese traditional medicine capsule for treating hyperthyroidism and simple goiter
CN1238013C (en) Myocarditis treating Chinese medicine prepn
CN1076622C (en) Chinese medicine for curing nephritis
CN1115160C (en) Orally-applied medicine for treating hyperosteogeny
CN104623368A (en) Decoction medicine for treating chronic glomerulonephritis and preparation method thereof
CN1435217A (en) Bone-strengthening medicine and producing method thereof
CN113713078A (en) Traditional Chinese medicine formula for treating diabetes mellitus with peripheral neuropathy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071031

Termination date: 20100704